Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures

JAMA

Volumn 302, Issue 1, 2009, Pages 58-66

  Cahill, Kevin S ^a   Chi, John H ^a   Day, Arthur ^a   Claus, Elizabeth B ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DYSPHAGIA; FEMALE; HEMATOMA; HOARSENESS; HOSPITAL CHARGE; HUMAN; INTERVERTEBRAL DISK HERNIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SEROMA; SPINE FUSION; AGED; CERVICAL SPINE; COHORT ANALYSIS; DRUG UTILIZATION; ECONOMICS; LUMBAR VERTEBRA; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; UNITED STATES; VERTEBRA;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; CERVICAL VERTEBRAE; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HOSPITAL CHARGES; HUMANS; LENGTH OF STAY; LINEAR MODELS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SPINAL FUSION; THORACIC VERTEBRAE; UNITED STATES;

EID: 67649967683     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.956     Document Type: Article

References (42)

1. Cypress BK. Characteristics of physician visits for back symptoms: a national perspective. Am J Public Health. 1983;73(4):389-395.
2. Deyo RA, Cherkin D, Conrad D, Volinn E. Cost, controversy, crisis: low back pain and the health of the public. Annu Rev Public Health. 1991;12:141-156.
3. Martin BI, Deyo RA, Mirza SK, et al. Expenditures and health status among adults with back and neck problems. JAMA. 2008;299(6):656-664.
4. Lipson SJ. Spinal-fusion surgery-advances and concerns. N Engl J Med. 2004;350(7):643-644.
5. Urist MR, Huo YK, Brownell AG, et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci U S A. 1984;81(2):371-375.
6. US Food and Drug Administration. InFUSE Bone Graft/LT-CAGE Lumbar Tapered Fusion Device - P000058 [Web page]. http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm083423.htm.pdf. Updated May 7, 2009. Accessed June 5, 2009.
7. US Food and Drug Administration. OP-1 Putty - H020008 [Web page]. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm081181.htm. Updated May 8, 2009. Accessed June 5, 2009.
8. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am. 2005;87(6):1205-1212.
9. Vaccaro AR, Whang PG, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J. 2008;8(3):457-465.
10. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/ compression resistant matrix versus iliac crest bone graft. Spine. 2006;31(22):2534-2539.
11. Dickerman RD, Reynolds AS, Morgan BC, Tompkins J, Cattorini J, Bennett M. rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys! Spine J. 2007;7(4):508-509.
12. Buttermann GR. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J. 2008;8(3):426-435.
13. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19(7):483-486.
14. Pradhan BB, Bae HW, Dawson EG, Patel VV, Delamarter RB. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine. 2006;31(10):E277-E284.
15. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine. 2006;31(24):2813-2819.
16. Tumialán LM, Pan J, Rodts GE, Mummaneni PV. The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients. J Neurosurg Spine. 2008;8(6):529-535.
17. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine. 2002;27(16)(suppl 1):S40-S48.
18. Vaidya R, Carp J, Sethi A, Bartol S, Craig J, Les CM. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J. 2007;16(8):1257-1265.
19. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine. 2006;31(5):542-547.
20. US Food and Drug Administration Public Health Notification. Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. July 1, 2008. http://www.fda.gov/cdrh/safety/070108-rhbmp.html. Accessed June 5, 2009.
21. Agency for Healthcare Research and Quality. Healthcare and Utilzation Project Overview of the Nationwide Inpatient Sample (NIS). http://www.hcup-us. ahrq.gov/nisoverview.jsp. Updated July 11, 2008. Accessed June XX, 2009.
22. Deyo RA, Gray DT, Kreuter W, Mirza S, Martin BI. United States trends in lumbar fusion surgery for degenerative conditions. Spine. 2005;30(12):1441-1445.
23. Wang MC, Chan L, Maiman DJ, Kreuter W, Deyo RA. Complications and mortality associated with cervical spine surgery for degenerative disease in the United States. Spine. 2007;32(3):342-347.
24. Shamji MF, Cook C, Pietrobon R, Tackett S, Brown C, Isaacs RE. Impact of surgical approach on complications and resource utilization of cervical spine fusion: a nationwide perspective to the surgical treatment of diffuse cervical spondylosis. Spine J. 2009;9(1):31-38.
25. Shamji MF, Cook C, Tackett S, Brown C, Isaacs RE. Impact of preoperative neurological status on perioperative morbidity associated with anterior and posterior cervical fusion. J Neurosurg Spine. 2008;9(1):10-16.
26. Davis H. Increasing rates of cervical and lumbar spine surgery in the United States, 1979-1990. Spine. 1994;19(10):1117-1123.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
29. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
30. Patil PG, Turner DA, Pietrobon R. National trends in surgical procedures for degenerative cervical spine disease: 1990-2000. Neurosurgery. 2005;57(4):753-758.
31. Liu JH, Zingmond DS, McGory ML, et al. Disparities in the utilization of high-volume hospitals for complex surgery. JAMA. 2006;296(16):1973-1980.
32. Deyo RA, Mirza SK. Trends and variations in the use of spine surgery. Clin Orthop Relat Res. 2006;443:139-146.
33. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery. 2008;62(5)(suppl 2):ons423-ONS431.
34. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290(14):1868-1874.
35. Romano PS, Chan BK, Schembri ME, Rainwater JA. Can administrative data be used to compare postoperative complication rates across hospitals? Med Care. 2002;40(10):856-867.
36. McCarthy EP, Iezzoni LI, Davis RB, et al. Does clinical evidence support ICD-9-CM diagnosis coding of complications? Med Care. 2000;38(8):868-876.
37. Brasel KJ, Lim HJ, Nirula R, Weigelt JA. Length of stay: an appropriate quality measure? Arch Surg. 2007;142(5):461-465.
38. Rosenthal GE, Harper DL, Quinn LM, Cooper GS. Severity-adjusted mortality and length of stay in teaching and nonteaching hospitals: results of a regional study. JAMA. 1997;278(6):485-490.
39. Schmidt WP, Taeger D, Buecker-Nott HJ, Berger K. The impact of the day of the week and month of admission on the length of hospital stay in stroke patients. Cerebrovasc Dis. 2003;16(3):247-252.
40. Friedman B, De La Mare J, Andrews R, McKenzie DH. Practical options for estimating cost of hospital inpatient stays. J Health Care Finance. 2002;29(1):1-13.
41. Glassman SD, Carreon LY, Campbell MJ, et al. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. Spine J. 2008;8(3):443-448.
42. Ackerman SJ, Mafilios MS, Polly DW Jr. Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion: an evidence-based modeling approach. Spine. 2002;27(16)(suppl 1):S94-S99.